Haney-Williams v. GlaxoSmithKline LLC

CourtDistrict Court, D. Nevada
DecidedJanuary 14, 2022
Docket2:17-cv-02900
StatusUnknown

This text of Haney-Williams v. GlaxoSmithKline LLC (Haney-Williams v. GlaxoSmithKline LLC) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Haney-Williams v. GlaxoSmithKline LLC, (D. Nev. 2022).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 DISTRICT OF NEVADA 6 * * *

7 DEVRA HANEY-WILLIAMS, Case No. 2:17-CV-2900 JCM (EJY)

8 Plaintiff(s), ORDER

9 v.

10 GLAXOSMITHKLINE LLC, et al.,

11 Defendant(s).

12 13 Presently before the court is third-party defendant Jubilant Cadista Pharmaceuticals, 14 Inc.’s (“Jubilant”) motion to dismiss (ECF No. 108) third-party plaintiff Sam’s West, Inc.’s 15 (“Sam’s West”) third-party complaint (ECF No. 100). Sam’s West filed a response in opposition 16 (ECF No. 119), to which Jubilant replied (ECF No. 122). 17 Also before the court is Jubilant’s motion for summary judgment (ECF No. 135) as to 18 Sam’s West’s third-party complaint. Sam’s West filed a response (ECF No. 147), to which 19 Jubilant replied (ECF No. 158). 20 I. BACKGROUND 21 This action arises from injuries that plaintiff Devra Haney-Williams (“Devra”) allegedly 22 suffered as a result of her use of Lamotrigine, a generic prescription medication. (ECF No. 100). 23 Devra originally filed her complaint in Nevada state court in October 2017. (ECF No. 1). The 24 action was subsequently removed to federal court on November 20, 2017. (ECF No. 1). On 25 November 13, 2018, Devra filed a first amended complaint adding Jubilant as a defendant. (ECF 26 No. 30). Jubilant was eventually dismissed from the suit (ECF No. 69), but Sam’s West obtained 27 28 1 leave of this court to file a third-party complaint against Jubilant (ECF No. 98). The third-party 2 complaint (ECF No. 100) contains the following allegations1: 3 Jubilant is a pharmaceutical company that manufactures Lamotrigine, a generic 4 prescription drug used to treat epilepsy. (Id. at 3). On September 25, 2015, Devra was 5 prescribed Lamotrigine. (Id.). On October 6, 2015, Sam’s Pharmacy #10-4974 at 2650 East 6 Craig Road, North Las Vegas, Nevada (“Sam’s Pharmacy”) “correctly” dispensed one bottle of 7 100mg tablets of Lamotrigine to Devra as directed by an electronic prescription transmitted to 8 Sam’s West by Devra’s prescribing physician. (Id.). On October 13, 2015, Devra began taking 9 the 100mg tablets of Lamotrigine at a rate of one tablet per day, ultimately resulting in injuries 10 and damages, including a diagnosis of Toxic Epidermal Necrolysis (the “incident”).2 (Id. at 3). 11 On January 13, 2010, Sam’s West entered into a written supplier agreement (the 12 “agreement”) with Jubilant to supply services and/or goods to Sam’s West. (Id.). The 13 agreement included an indemnity clause. (Id. at 4). The agreement was amended in January 14 2015 and updated on October 19, 2015, potentially indicating the agreement was in force and 15 effect at the time of the incident in October 2015. (Id. ¶ 13). 16 Sam’s West alleges causes of action for contractual indemnity, breach of contract, 17 contribution, and declaratory relief. (ECF No. 100). Jubilant now moves to dismiss Sam’s 18 West’s third-party complaint for failure to state a claim upon which relief can be granted (ECF 19 No. 108), or, in the alternative, moves for summary judgment (ECF No. 158) as to the third-party 20 complaint. 21 II. LEGAL STANDARD 22 Federal Rule of Civil Procedure 8 requires every complaint to contain a “short and plain 23 statement of the claim showing that the pleader is entitled to relief.” FED. R. CIV. P. 8. Although 24 Rule 8 does not require detailed factual allegations, it does require more than “labels and

25 1 At the motion to dismiss stage, the court is required to accept as true all well-pleaded 26 allegations. Accordingly, the well-pleaded facts presented here are assumed to be true. Legal conclusions are not entitled to this assumption of truth. 27 2 Plaintiff alleges in her first amended complaint that the Toxic Epidermal Necrolysis 28 caused “blistering and loss of skin over eighty percent of her body, including tissue covering her eyes, rendering her permanently blind,” (See ECF No. 30 ¶ 21). 1 conclusions” or a “formulaic recitation of the elements of a cause of action.” Ashcroft v. Iqbal, 2 556 U.S. 662, 678 (2009) (citation omitted). In other words, a complaint must have plausible 3 factual allegations that cover “all the material elements necessary to sustain recovery under some 4 viable legal theory.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 562 (2007) (citation omitted) 5 (emphasis in original); see also Mendiondo v. Centinela Hosp. Med. Ctr., 521 F.3d 1097, 1104 6 (9th Cir. 2008). 7 The Supreme Court in Iqbal clarified the two-step approach to evaluate a complaint’s 8 legal sufficiency on a Rule 12(b)(6) motion to dismiss. First, the court must accept as true all 9 well-pleaded factual allegations and draw all reasonable inferences in the plaintiff’s favor. Iqbal, 10 556 U.S. at 678–79. Legal conclusions are not entitled to this assumption of truth. Id. Second, 11 the court must consider whether the well-pleaded factual allegations state a plausible claim for 12 relief. Id. at 679. A claim is facially plausible when the court can draw a reasonable inference 13 that the defendant is liable for the alleged misconduct. Id. at 678. When the allegations have not 14 crossed the line from conceivable to plausible, the complaint must be dismissed. Twombly, 550 15 U.S. at 570; see also Starr v. Baca, 652 F.3d 1202, 1216 (9th Cir. 2011). 16 The Ninth Circuit addressed post-Iqbal pleading standards in Starr v. Baca, 652 F.3d 17 1202, 1216 (9th Cir. 2011). The Starr court held, 18 First, to be entitled to the presumption of truth, allegations in a complaint or 19 counterclaim may not simply recite the elements of a cause of action, but must contain sufficient allegations of underlying facts to give fair notice and to enable 20 the opposing party to defend itself effectively. Second, the factual allegations that are taken as true must plausibly suggest an entitlement to relief, such that it is not 21 unfair to require the opposing party to be subject to the expense of discovery and continued litigation. 22 Id. 23 If the court grants a Rule 12(b)(6) motion to dismiss, it should grant leave to amend 24 unless the deficiencies cannot be cured by amendment. DeSoto v. Yellow Freight Sys., Inc., 957 25 F.2d 655, 658 (9th Cir. 1992). Under Rule 15(a), the court should “freely” give leave to amend 26 “when justice so requires,” and absent “undue delay, bad faith, or dilatory motive on the part of 27 the movant, repeated failure to cure deficiencies by amendments . . . undue prejudice to the 28 opposing party . . . futility of the amendment, etc.” Foman v. Davis, 371 U.S. 178, 182 (1962). 1 The court should grant leave to amend “even if no request to amend the pleading was made.” 2 Lopez v. Smith, 203 F.3d 1122, 1127 (9th Cir. 2000) (en banc) (internal quotation marks 3 omitted). 4 III. DISCUSSION 5 The court will first address the motion to dismiss as a threshold matter, and then turn to 6 the motion for summary judgment, as necessary. 7 In deciding the motion to dismiss, the court must resolve two larger questions: 1) Was 8 there an effective agreement at the time of the incident?; and 2) If so, does the indemnity clause 9 apply? If no effective agreement existed, the inquiry ends and the motion to dismiss must be 10 granted.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ricard v. Williams
20 U.S. 59 (Supreme Court, 1822)
Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Gul v. Obama
652 F.3d 12 (D.C. Circuit, 2011)
Knittle v. Progressive Casualty Insurance
908 P.2d 724 (Nevada Supreme Court, 1996)
Mendiondo v. Centinela Hospital Medical Center
521 F.3d 1097 (Ninth Circuit, 2008)
Wallace v. Motor Products Corporation
25 F.2d 655 (Sixth Circuit, 1928)
Arkansas Kraft Corp. v. Boyed Sanders Construction Co.
764 S.W.2d 452 (Supreme Court of Arkansas, 1989)
Potlatch Corp. v. Missouri Pacific Railroad
902 S.W.2d 217 (Supreme Court of Arkansas, 1995)
State v. Hoadley
22 P. 99 (Nevada Supreme Court, 1889)
Lindsay Cooper v. Tokyo Elec. Power Co. Holdings
960 F.3d 549 (Ninth Circuit, 2020)
Lopez v. Smith
203 F.3d 1122 (Ninth Circuit, 2000)
Starr v. Baca
652 F.3d 1202 (Ninth Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Haney-Williams v. GlaxoSmithKline LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/haney-williams-v-glaxosmithkline-llc-nvd-2022.